We are hiring a motivated cell culture technician! Apply here:
ATANIS Biotech AG
Biotechnologie
Oberkirch, Lucerne 3.240 Follower:innen
We revolutionize allergy diagnosis
Info
ATANIS Biotech AG has been incorporated as a spin-off company from the University of Bern by the four co-founders Mrs. Noemi Zbären, Prof. Thomas Kaufmann, Prof. Alexander Eggel and Prof. Jean-Pierre Kinet in Summer 2021. The company has developed a novel functional cell based assay that massively simplifies the diagnosis of allergies and can predict treatment success of therapies. This test will additionally be used to assess safety and efficacy of potential new drug candidates for allergy treatment as well as for the evaluation of allergenicity of various food products. The proprietary assay is offered through a fee-for-service business model to our customers all over the world. Contact us at: [email protected]
- Branche
- Biotechnologie
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Oberkirch, Lucerne
- Art
- Privatunternehmen
- Gegründet
- 2021
- Spezialgebiete
- Allergy, Diagnostics, In vitro testing, Fee for service, Pre-clinical assessments, Clinical Trials, Food Products und Allergenicity
Orte
-
Primär
Wegbeschreibung
Hubelmatte 26
Oberkirch, Lucerne 6208, CH
Beschäftigte von ATANIS Biotech AG
-
Jean-Pierre Kinet
CEO of ATANIS Biotech AG (Bern, Switzerland). Professor Emeritus (Harvard Medical School). Chairman and Managing Partner iXLife
-
Saskia Brunner-Agten
Résponsable Scientifique bei Laboratoire Salamin
-
Alexander Eggel
Associate Professor at University of Bern, Immunologist, Allergy & Aging Researcher, Entrepreneur
-
Thomas Kaufmann
Associate Prof. at University of Bern
Updates
-
We are #hiring a certified clinical laboratory technician. If a) you want to help deliver a novel diagnostic test to patients and b) you are certified in CH (or can have your certification recognized by SRK), please reach out!
-
We are hiring, come and contribute to revolutionizing allergy testing! https://lnkd.in/gpy7Ethw
-
ATANIS Biotech AG hat dies direkt geteilt
“There is one thing we ALL have in common in this room today. No, it’s not just being nerds.. 😉 No, it’s not only to develop novel therapies and commercial advancements. No, it’s not to obtain funding for research. It’s deeper than all of that. A mother’s desperation and love brought us here & together we want to end fragmented medicine, research and commercial availability to patients and families living with food allergies. And THAT is why we do what we CAN do to end the many obstacles to a treatment and a cure. It’s personal. It’s human.” Thank you, Food Allergy Fund for having me. Mom to Mom. 🫶🏻
-
-
-
-
-
+7
-
-
Great line-up of speakers at the 9th Food Allergy Fund Summit in New York City! We are happy to be part of this exciting scientific program. See you there! #FoodAllergy, #FunctionalDiagnosis, #FAST-PASE, #Hoxb8MAT, #SwissMade, Lisa Shapiro Strovink, Beat U. Steffen, RAC, FRAPS, IgGenix, Inc
We are excited to announce our CEO panel, which includes Jessica Grossman MD, CEO of IgGenix, Inc.; Nikole Kimes, CEO of Siolta Therapeutics; and Jean-Pierre Kinet, CEO of ATANIS Biotech AG. From developing a peanut allergy therapeutic to creating a microbiome-based therapeutic for atopic disease to revolutionizing the diagnosis of allergies, these CEOs and their companies are doing groundbreaking work to help everyone with allergies. To learn more and register for the 9th Food Allergy Fund Summit on May 23, visit https://lnkd.in/gs2tzeKu. #foodallergy #therapeutics #research
-